2010 Scrip 100 - Little change in win, place or show
This article was originally published in Scrip
Executive Summary
When examining the competitiveness of company pipelines, and the extent of a company's R&D commitment, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials activity as opposed to the overall number of drugs in the pipeline. Clinical trial activity was assessed over the 12-month period from September 2008 to August 2009, using data from TrialTrove where trial start dates were disclosed in the public domain.
You may also be interested in...
2017 Completed Trials: Status Quo Or No?
Trialtrove data provides window onto the landscape of industry-sponsored clinical trials completed during 2017.
Turn back time: oncology trials are getting shorter
It is widely accepted in the biopharmaceutical industry that clinical trial protocols are growing in complexity; many in the business bewail that the duration of trials is increasing, with patient enrollment a frequently-cited problem in clinical development.
Market Insight - Clinical trials metrics tell all about pharma's R&D investment
When examining the competitiveness of company pipelines and the extent of firms' commitment to R&D, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials' activity as opposed to the overall number of drugs in the pipeline. Using data from TrialTrove for the 12-month period from September 1st, 2008, to August 31st, 2009, where trial start dates were disclosed in the public domain, trial activity was analysed to determine overall rankings by industry sponsor and company R&D spend per trial.